Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.37 |
| ▸ | GHSR | Q92847 | 3/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | CALCR | P30988 | 4/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 4/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070351 | 1.00 | APLNR (0.37) | APLNRGHSRMC4RCALCRCRHR1 | |
| SCHEMBL17168143 | 0.92 | APLNR (0.39) | APLNRGHSRMC4RCALCRF2 | |
| SCHEMBL2623712 | 0.80 | APLNR (0.40) | APLNRCRHR1CRHR2F2CAPN1 | |
| SCHEMBL15744687 | 0.80 | APLNR (0.40) | APLNRGHSRMC4RCRHR1CRHR2 | |
| SCHEMBL22387819 | 0.77 | CTSS (0.40) | CAPN1OPRK1 | |
| SCHEMBL15745525 | 0.75 | APLNR (0.36) | APLNRCALCRCRHR1CRHR2 | |
| SCHEMBL19084162 | 0.74 | APLNR (0.36) | APLNRGHSRCRHR1CRHR2F2 | |
| SCHEMBL26019657 | 0.74 | CTSS (0.40) | APLNRCAPN1OPRK1 | |
| SCHEMBL15744682 | 0.74 | MMP3 (0.40) | APLNRGHSRCALCRCRHR1CRHR2 | |
| SCHEMBL13624749 | 0.69 | CTSS (0.48) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4524569-A2 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | AF Chemical LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3667323-B1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | AF CHEMICAL LLC (US) | 2024-11-13 | — | — | EP | disclosed |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | AF CHEMICALS, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11591295-B2 | Affinity illudofulvene conjugates | AF CHEMICALS LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4035684-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | AF Chemical LLC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11241398-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-11160807-B1 | Methods, compositions and devices for treating cancer with illudofulvenes | AF CHEMICALS, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-11135182-B2 | Affinity medicant conjugates | AF CHEMICALS, LLC (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210155583-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | AF CHEMICALS, LLC | 2021-05-27 | — | — | US | disclosed |
| US-20210077425-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| EP-3667323-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | Kelner, Michael (US) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160807-B1 | Methods, compositions and devices for treating cancer with illudofulvenes | MYC, MYCBP, TP53 | APLNR 37/4885GHSR 890/4885MC4R 2996/4885 |
| US-11591295-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | APLNR 95/4885GHSR 401/4885MC4R 422/4885 |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | MYC, MYCBP, TP53 | APLNR 37/4885GHSR 890/4885MC4R 2996/4885 |
| US-20210155583-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | APLNR 95/4885GHSR 401/4885MC4R 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.